|  |  | Interpretive Criteriatrue1false | Epidemiologic Cut-off Valuetrue2false |
| --- | --- | --- | --- |
| Antimicrobial | Class | Abbreviation | S | I | R | NS | Host Species | Sitetrue3false | Bacterial Species | ECOFF | ECOFF Bacterial Species |
| Amikacin | Aminoglycoside | AMIKAC | ≤ 4 | 8 | ≥ 16 | >4 | Dogs | not specified | all staphylococci | > 16 | S. aureus |
| Amoxicillin-clavulanate | Beta-Lactam | AMOCLA | ≤ 0.25 | 0.5 | ≥ 1 | >0.25 | Dogs | SST | all staphylococci | > 0.03true4false | S. pseudintermedius |
| Ampicillin | Beta-Lactam | AMPICI | ≤ 0.25 |  | ≥ 0.5 | >0.25 | Dogs | SST | S. pseudintermedius | > 0.5 | S. aureus |
| Cefazolin | Beta-Lactam | CEFAZO | ≤ 2 | 4 | ≥ 8 | >2 | Dogs | SST, Resp, UTI | S. pseudintermedius | > 2 | S. aureus |
| Cefovecin | Beta-Lactam | CEFOVE | ≤ 0.5 | 1 | ≥ 2 | >0.5 | Dogs | SST | S. pseudintermedius | NA |  |
| Cefpodoxime | Beta-Lactam | CEFPOD | ≤ 2 | 4 | ≥ 8 | >2 | Dogs | wounds/abscesses | S. pseudintermedius | NA |  |
| Ceftiofur | Beta-Lactam | CEFTIF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | > 2 | S. aureus |
| Cephalothin | Beta-Lactam | CEPHAL | ≤ 2 | 4 | ≥ 8 | >2 | Dogs | SST | S. pseudintermedius | > 1true4false | S. aureus |
| Chloramphenicol | Phenicol | CHLORA | ≤ 8 | 16 | ≥ 32 | >8 | Humans | not specified | all staphylococci | > 16 | S. aureus |
| Chloramphenicol\_newBPtrue5false | Phenicol | CHLORA.newBP | ≤ 2 | 4 | ≥ 8 | >2 | Dogs |  | all staphylococci | NA | NA |
| Clindamycin | Macrolide/Lincosamide | CLINDA | ≤ 0.5 | 1, 2 | ≥ 4 | >0.5 | Dogs | SST | all staphylococci | > 0.25true4false | S. pseudintermedius |
| Doxycycline | Tetracycline | DOXYCY | ≤ 0.12 | 0.25 | ≥ 0.5 | >0.12 | Dogs | SST | S. pseudintermedius | > 0.125 | S. pseudintermedius |
| Enrofloxacin | Fluoroquinolone | ENROFL | ≤ 0.5 | 1, 2 | ≥ 4 | >0.5 | Dogs | SST, UTI, Resp | all staphylococci | > 0.5 | S. pseudintermedius |
| Enrofloxacin\_newBPtrue5false | Fluoroquinolone | ENROFL.newBP | ≤ 0.25 |  | ≥ 0.5 | >0.25 | Dogs | SST, UTI, Resp | all staphylococci | NA | NA |
| Erythromycin | Macrolide/Lincosamide | ERYTH | ≤ 0.5 | 1,2,4 | ≥ 8 | >0.5 | Humans | not specified | all staphylococci | > 0.5 | S. pseudintermedius |
| Gentamicin | Aminoglycoside | GENTAM | ≤ 4 | 8 | ≥ 16 | >4 | Humans | not specified | all staphylococci | > 0.25true4false | S. pseudintermedius |
| Marbofloxacin | Fluoroquinolone | MARBOF | ≤ 1 | 2 | ≥ 4 | >1 | Dogs | SST, UTI | all staphylococci | NA |  |
| Marbofloxacin\_newBPtrue5false | Fluoroquinolone | MARBOF.newBP | ≤ 0.25 |  | ≥ 0.5 | >0.25 | Dogs | SST, UTI | all staphylococci | NA | NA |
| Minocycline | Tetracycline | MINOCY | ≤ 0.5 | 1 | ≥ 2 | >0.5 | Dogs | SST | S. pseudintermedius | > 0.5 | S. aureus |
| Nitrofurantoin | Nitrofuran | NITRO | ≤ 32 | 64 | ≥ 128 | >32 | Humans | UTI | all staphylococci | > 32 | S. aureus |
| Oxacillin | Beta-Lactam | OXACIL | ≤ 0.25 |  | ≥ 0.50 | >0.25 | Humans | not specified | S. pseudintermedius | > 2 | S. aureus |
| Penicillin | Beta-Lactam | PENICI | ≤ 0.12 |  | ≥ 0.25 | >0.12 | Humans | not specified | all staphylococci | NA |  |
| Pradofloxacin | Fluoroquinolone | PRADOF | ≤ 0.25 | 0.5, 1 | ≥ 2 | >0.25 | Dogs | SST, UTI | S. pseudintermedius | NA |  |
| Rifampin | Ansamycin | RIFAMP | ≤ 1 | 2 | ≥ 4 | >1 | Humans | not specified | all staphylococci | > 0.03true4false | S. aureus |
| Tetracycline | Tetracycline | TETRA | ≤ 0.25 | 0.5 | ≥ 1 | >0.25 | Dogs | SST | all staphylococci | > 1 | S. pseudintermedius |
| Trimethoprim-Sulfamethoxazole | Sulfonamide | TRISUL | ≤ 2 |  | ≥ 4 | >2 | Humans | not specified | all staphylococci | > 0.25true4false | S. aureus |
| Vancomycin | Glycopeptide | VANCOM | ≤ 4 | 8, 16 | ≥ 32 | >4 | Humans | not specified | all staphylococci other than S. aureus | > 2true4false | S. aureus |
| *1*Interpretive Criteria sourced from CLSI VET01S Ed6, except for new BP from Ed7 |
| *2*ECOFF sourced from EUCAST, October 13, 2023 |
| *3*Resp: Respiratory; SST: Skin/Soft Tissue; UTI: Urinary Tract Infection |
| *4*ECOFF falls within the susceptible category and splits the wildtype population |
| *5*newBP refers to breakpoints that will be in CLSI VET01S7 |